The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
about
Oncogenic kinase fusions: an evolving arena with innovative clinical opportunitiesEosinophilia in Hematologic DisordersWill the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?Hypereosinophilic syndrome with cardiac involvement in a pregnant patient with multiple sclerosis.FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophiliaHypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.Eosinophilic myeloproliferative disordersA phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumorsIdentification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRAMoving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation statusLong-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody.Therapeutic approaches to patients with hypereosinophilic syndromes.A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.How I treat hypereosinophilic syndromes.The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 CasesComparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersLarge apical thrombus in a patient with persistent heart failure and hypereosinophilia: Löffler endocarditisPreclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study.Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activitiesSpontaneous liver rupture in hypereosinophilic syndrome: a rare but fatal complication.Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia.FIP1L1-PDGFRA fusion-negative hypereosinophilic syndrome with uncommon cardiac involvement responding to imatinib treatment: A case report.
P2860
Q26768158-9182730E-570C-41B7-8DA7-E1C1FAA20606Q26799611-AD1E60AE-D853-4BAB-94C1-DF5A0FBB4021Q27023383-2FE62126-FFD7-47F8-91B5-87323E5C7C6CQ33394921-D4AE93CC-BCC8-40A3-AE5D-F5346B18A15EQ33404894-DAF87F97-A5A9-4B2C-8F34-45F2557A8B60Q33620407-A790CDDC-33BA-4421-B491-9A2429EC73B6Q33718814-B649E8BC-C1A0-4679-A8A3-F98C10925A38Q33829070-CEC8AB17-099A-4430-BC71-14AB9526F04DQ33881283-E410B761-6CE4-4C5B-BEF8-825463C46886Q34403375-FFDB36DE-1736-402E-BBE4-6463B584FA6CQ35114558-8B3FA0F2-4C27-4B40-941B-EBAACF5B2305Q35117747-17742752-07E6-4049-8F95-AEE444021643Q35575492-22E72049-9E51-4CEE-A931-BE42E82502E3Q35652636-4BFA19C4-3B29-4C14-AB5F-C112575497D9Q35857340-A905726D-0621-4529-A001-27485D16DD98Q35865095-133E9710-334F-49A7-B12B-E314DE8739E6Q36000858-97E46E1E-7D73-4154-9FE7-0CDE886AA3F0Q36008991-4CDC85BC-F264-493D-9293-5B55A563E2EFQ36374813-12EAF79A-BC31-4C20-B79E-ECD05B487B0CQ36870486-DC9B61BC-6EC1-4875-9EF4-B4664493377AQ37327244-E7D2A371-0E10-4591-9D68-938A35617B09Q37362888-8B1B3F10-D10C-4908-ACCC-6D5A06142FCBQ38131481-25611A1C-B510-442C-85CF-B9C9DA226D6BQ40822125-5F73F9ED-B2B0-4544-A0BE-13391F322D42Q41402735-8E0C17E6-8D32-436A-A748-3FBD3CD03F3BQ41786014-E47FA425-DB83-456A-8DD2-405CC965689EQ42030211-D6B37C8E-6A4F-435F-B749-F71D5E528F9BQ42704283-0BF408E1-E6AA-4999-A18B-A21A42D66D45Q55411628-CAB6F263-70B7-4141-975B-3DE6F86460C8
P2860
The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
description
im August 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 August 2007
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2007
@uk
name
The efficacy of imatinib mesyl ...... multicenter prospective study
@en
The efficacy of imatinib mesyl ...... multicenter prospective study
@nl
type
label
The efficacy of imatinib mesyl ...... multicenter prospective study
@en
The efficacy of imatinib mesyl ...... multicenter prospective study
@nl
prefLabel
The efficacy of imatinib mesyl ...... multicenter prospective study
@en
The efficacy of imatinib mesyl ...... multicenter prospective study
@nl
P2093
P50
P356
P1433
P1476
The efficacy of imatinib mesyl ...... multicenter prospective study
@en
P2093
Antonio de Vivo
Cinzia Astolfi
Daniela Cilloni
Emanuela Ottaviani
Emilia Giugliano
Enrico Gottardi
Fabrizio Pane
Francesca Messa
Francesca Rancati
Gianantonio Rosti
P304
P356
10.3324/HAEMATOL.11420
P407
P50
P577
2007-08-01T00:00:00Z